Loading data for ATTO — first visit, this takes a few seconds.

Attovia Therapeutics, Inc. (ATTO)

NasdaqGM: ATTO · Echtzeitkurs · USD

23.13

+0.91 (4.10%)

Zum Schluss: Sep 02, 2026, 3:59 PM

23.37

+1.05%

Nachbörslich: 7:30 PM

Preisalarm

Alert

Kurs, die wichtigsten Kennzahlen und die neuesten Nachrichten an einem Ort.

4.10% (1D)

Geld	n/a
Marktkapitalisierung	995M
Umsatz (TTM)	1.35M
Nettogewinn (TTM)	-64.1M
	0.00
	-2.61
	n/a
	-9.86
KBV (TTM)	-0.83
KUV (TTM)	737.23
Termin Quartalszahlen	n/a

Brief	n/a
Volumen	81,162
Ø Vol. (20D)	503,850
Eröffnung	22.40
Vortagesschluss	22.22
Tagesspanne	21.70 - 23.48
52-Wk Range	16.15 - 24.32
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über ATTO

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch ...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Aug 5, 2026

Mitarbeiter 44

Börse NasdaqGM

Tickersymbol ATTO

Website https://www.attovia.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Attovia Therapeutics 1.35 Mio, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -60.63 Mio, ein Anstieg von 52.33 %.

Finanzberichte

Gewinnüberraschung

Attovia Therapeutics hat die Quartalszahlen am Invalid Date veröffentlicht:

Umsatz von n/a verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.
EPS von verfehlt die Erwartungen um , mit NaN% Wachstum im Jahresvergleich.

Warum der Kurs sich bewegte

Nachrichten

vor 2 Tagen · MT Newswires

Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says

Attovia Therapeutics' (ATTO) ATTOBODY platform should position the company as a key player in immuno

vor 2 Tagen · The Fly

Deere upgraded, Lumentum initiated: Wall Street's top analyst calls

vor 2 Tagen · 24/7 Wall St.

Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More

Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that cou...

vor 1 Woche · Trefis

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

vor 1 Woche · Trefis

Moderna Stock Had A Readout Waiting In Plain Sight

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

Seite 1 von 2

Attovia Therapeutics, Inc. (ATTO)